Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis exp

Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives op

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) reached a new 52-week low on Monday. Th

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating

– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinu

Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an inve

Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs t

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Pe

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy a

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III L

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascul

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and mai

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Pe

FDA approves Zanvastro from Ionis Pharmaceuticals as the first disease-modifying treatment for rare

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/down

Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst r

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and pri

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

Wall Street analysts changed outlook on top names: Barclays cut META price target, Needham boosted Q

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

U.S. stock futures advanced on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose,

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

U.S. stock futures mixed, Dow down 0.1%. Levi Strauss shares down 6.1%, Noah Holdings down 14%, Ioni

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes